Title : Rivastigmine in Alzheimer disease: efficacy over two years - Grossberg_2004_Am.J.Geriatr.Psychiatry_12_420 |
Author(s) : Grossberg G , Irwin P , Satlin A , Mesenbrink P , Spiegel R |
Ref : American Journal of Geriatry & Psychiatry , 12 :420 , 2004 |
Abstract :
OBJECTIVE: Beyond 6 to 9 months of treatment with cholinesterase inhibitors (ChE-Is), there is a notable increase in the rate of cognitive decline in Alzheimer disease (AD) patients, and there are few longer-term studies to evaluate this finding. The authors examined whether the ChE-I rivastigmine continued to be therapeutically effective after up to 2 years of treatment in 2,010 patients with probable AD. |
PubMedSearch : Grossberg_2004_Am.J.Geriatr.Psychiatry_12_420 |
PubMedID: 15249280 |
Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R (2004)
Rivastigmine in Alzheimer disease: efficacy over two years
American Journal of Geriatry & Psychiatry
12 :420
Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R (2004)
American Journal of Geriatry & Psychiatry
12 :420